NGNE (Neurogene) OCF Margin %: 0.00% (As of Mar. 2026)


NGNE Neurogene Inc NGNE
12 GF Score
Price $32.05
! 4 Warning Signs
View Full Analysis

What is Neurogene OCF Margin %?

Neurogene NGNE +5.26% 12 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates NGNE with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 958 Biotechnology companies, Neurogene ranks worse than 104384.03% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Neurogene's Cash Flow from Operations for the three months ended in Mar. 2026 was $-26.12 Mil. Neurogene's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Neurogene's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Neurogene's current OCF Yield % is -16.29%.

The historical rank and industry rank for Neurogene's OCF Margin % or its related term are showing as below:


During the past 5 years, the highest OCF Margin % of Neurogene was -7632.76%. The lowest was -7632.76%. And the median was -7632.76%.

NGNE's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Neurogene OCF Margin % Related Terms

Neurogene OCF Margin % Historical Data

* Premium members only.

The historical data trend for Neurogene's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurogene OCF Margin % Chart

Neurogene Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
0.00 0.00 0.00 -7,632.76 0.00

Neurogene Quarterly Data
Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NGNE
12GF Score
Neurogene Inc NGNE
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurogene OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Neurogene's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-77.173/0
= %

Neurogene's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-26.119/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Neurogene (NGNE) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Neurogene and its competitors. According to the industry distribution chart, Neurogene ranks #999999 out of 958 companies in the Biotechnology industry.
Is Neurogene's OCF Margin % too high?
Neurogene's current OCF Margin % is 0.00%. Based on the distribution chart, Neurogene ranks #999999 out of 958 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Neurogene has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Neurogene's OCF Margin % compare to SGMT and IPSC?
According to the Biotechnology industry distribution chart, Neurogene ranks #999999 out of 958 companies for OCF Margin %. This places Neurogene in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Neurogene and its competitors. Neurogene's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurogene stock overvalued right now?
Neurogene (NGNE) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Neurogene's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Neurogene (NGNE), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurogene Business Description

Other Exchanges UU8:Germany
Address 535 W 24th Street, 5th Floor, New York, NY, USA, 10011
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
12GF Score

Get the complete analysis for NGNE

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.05
Price